In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AHF (AIDS Healthcare Foundation) engages in Mexican HIV/STI services investment partnership:

This article was originally published in Clinica

Executive Summary

The AIDS Healthcare Foundation, a US not-for-profit HIV/AIDS care, research and prevention organisation, yesterday opened its third centre for sexually-transmitted infections (STIs) and HIV in Mexico. In partnership with the government, which has unveiled plans to build a network of 51 so-called CAPASITS centres (see related story), the Cancun (Quintana Roo state) clinic joins those currently being run by AHF in Tijuana (since October 2005) and Puerto Vallarta (since November 2006). The AHF is planning to open a fourth clinic later this year in the city of La Paz (Baja California Sur state). The Los Angeles-based group also operates a similar centre in Guatemala, in the city of Quetzaltenango.

You may also be interested in...

Pandemic Response In US Consumer Health Market: OTC Pain Relief And Cough/Cold Purchases

Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.

venBio Raises $394m To Fund Biopharmas Through Human Proof-Of-Concept

Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.

FDA Wants To Put Hep C Tests On 510(k) Pathway

The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts